The effectiveness of the Russian vaccine Sputnik-V against Delta mutation of coronavirus touches the 94%, based on various data and recording methods, which means that it is much higher than the effectiveness of foreign vaccines, said on Friday (10/9) the Alexander Ginsburg, director of the Gamalei National Research Center for Epidemiology and Microbiology, which has developed this formulation.
“The effectiveness of the protection of the Sputnik-V vaccine, according to the data of the Ministry of Health as recorded today varies from 83% to 94%.
At the same time, the effectiveness of vaccines Pfizer and Modern, according to data from American and Israeli universities ranges from 40% and something up to 52%“, which of course is significantly worse”, he noted specifically, according to the APE BPE.
Ginsburg also pointed out that the epidemiological situation that emerged after the appearance of the Delta mutation “actually reset the vaccine market “.
According to him, one billion of the world’s population, who have been vaccinated with foreign vaccines, must be revaccinated to increase the number of corresponding antibodies to a fairly high level.
The director of the Gamalei Institute also said that in order to control the epidemic led by the Indian executive, the 70–75% of the population of Russia, as with such a percentage of vaccinated the disease will begin to decline.
He stressed, however, that we must constantly monitor new variant strains of coronavirus so that the vaccines remain effective.
Referring to the Delta mutation, he said that its appearance changed the tactics and strategy of coronavirus vaccination, as a high level of antibodies must now be maintained at all times.
Given this change, Ginzburg finally stated that the Russian Ministry of Health reacted very quickly to this changing situation and gave instructions, according to which citizens should be vaccinated with the vaccine. Sputnik- Light once every six months.
It is recalled that the European Medicines Agency (EMA) stated, however, that more information is needed on the Russian Sputnik-V coronavirus vaccine in order to continue the process of evaluating the preparation for use in Europe.